Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

The American Journal of Translational Research is a pivotal publication in the fields of Biochemistry, Genetics, and Molecular Biology, dedicated to advancing the understanding of translational science and its applications in clinical settings. Published by E-CENTURY PUBLISHING CORP, this journal, under ISSN 1943-8141, fosters scholarly exchange by publishing original research articles, reviews, and clinical studies that bridge the gap between laboratory discoveries and actual medical practice. Although its coverage in Scopus has been discontinued, the journal has previously held respectable rankings, including a 64th percentile in Clinical Biochemistry and 52nd in both Molecular Medicine and Cancer Research, indicating its influence and relevance in the scientific community. With its formal objective of disseminating significant findings that inform clinical practices, the journal remains a valuable resource for researchers, healthcare professionals, and students eager to stay at the forefront of translational research advancements.

EXPERIMENTAL BIOLOGY AND MEDICINE is a distinguished open-access journal published by FRONTIERS MEDIA SA, specializing in the interdisciplinary fields of biochemistry, genetics, and medicine. With an ISSN of 1535-3702 and an E-ISSN of 1535-3699, this journal presents a robust platform for cutting-edge research and innovative clinical studies. Since its inception in 1996, it has evolved to feature a broad scope that caters to the evolving needs of researchers, professionals, and students, ensuring a dynamic dissemination of knowledge in biological and medical sciences. In 2023, the journal achieved a notable Q2 ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories, reflecting its strong impact and relevance within the academic community, as supported by its Scopus rank of #59 out of 221 in general biochemistry and genetics, placing it in the 73rd percentile. By offering open access options, EXPERIMENTAL BIOLOGY AND MEDICINE aims to maximize the reach and visibility of research findings, fostering collaboration and knowledge sharing across global audiences. Researchers are encouraged to contribute to this vital resource as it continues to advance the understanding of biological mechanisms and therapeutic approaches crucial for modern medicine.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Welcome to Advances in Clinical and Experimental Medicine, an esteemed publication by WROCLAW MEDICAL UNIVERSITY, dedicated to advancing the essential fields of clinical and experimental medicine. With an open access model since 2017, this journal ensures that researchers, healthcare professionals, and students worldwide can freely access high-quality scientific content. Covering a broad spectrum of topics including biochemistry, genetics, internal medicine, and pharmacology, Advances in Clinical and Experimental Medicine has established itself as a pivotal resource in the scientific community, currently holding prestigious rankings such as Q2 in Biochemistry, Genetics, and Molecular Biology (miscellaneous) and Q1 in Reviews and References (medical) for 2023. Spanning over two decades of rigorous research publication, the journal is a critical platform for sharing innovative findings and fostering collaboration among scholars, making it an invaluable asset for those at the forefront of medical science.

Acta Facultatis Medicae Naissensis is an esteemed open-access journal published by the University of Niš, Faculty of Medicine, situated in Serbia. Since its inception in 2009, this journal has been a vital platform for the dissemination of innovative research findings in the field of Medicine, particularly focusing on miscellaneous areas within the discipline. With an ISSN of 0351-6083 and an E-ISSN of 2217-2521, it operates under a commitment to free accessibility, enhancing visibility for authors and readers alike since 2012. In the 2023 categorization, it holds a respectable Q4 ranking in Medicine (Miscellaneous) and positions itself at the 34th percentile among general medicine publications in Scopus, reflecting its growing academic impact. Researchers, professionals, and students seeking an interactive scholarly exchange in medicine will find Acta Facultatis Medicae Naissensis a rich resource, contributing significantly to the understanding of health sciences and clinical practice through its diverse range of articles.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.